Öz

Objective: This study aimed to investigate the etiology of hypertransaminasemia in children and to evaluate the clinical characteristics of patients based on age and underlying causes.

Material and Methods: A total of 210 pediatric patients aged between 1 month and 18 years who presented to the Pediatric Gastroenterology Outpatient Clinic with hypertransaminasemia were retrospectively analyzed. Hypertransaminasemia was defined as AST >50 IU/L and ALT >45 IU/L on at least two separate occasions within two months.

Results: The mean age of the patients was 5.36±5.30 years and 50.5% were female. At presentation, 30.5% were asymptomatic, with fever being the most common symptom (23.4%). Physical examination findings were normal in 53.8% of cases. Mean AST and ALT values were significantly higher in symptomatic patients compared to asymptomatic ones (p<0.001). No significant difference were observed between age groups in terms of mean ALT and AST values (p=0.290, p=0.190). Hypertransaminasemia was mild in 55.7% of patients, moderate in 20.5%, and severe in 23.8%. An underlying etiology was identified in 61% of cases. The most common cause was infectious diseases, followed by metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic/genetic disorders. Severe hypertransaminasemia was significantly more frequent in infectious diseases than in idiopathic cases or MASLD, whereas mild hypertransaminasemia was more common in MASLD and idiopathic cases compared to infections (p<0.001).

Conclusion: Infectious diseases and MASLD remain the leading causes of hypertransaminasemia in children. Infectious etiologies contribute across all age groups, MASLD is strongly linked to obesity and adolescence. As elevated transaminase levels may be the only clinical clue, especially in asymptomatic patients with normal physical examinations, careful follow-up and comprehensive evaluation are essential to avoid potential complications.

Anahtar Kelimeler: ALT, AST, infectious diseases, NAFLD, pediatric, transaminases

Kaynakça

  1. Arnal IR, Andrade JR, Hally MM, Baviera LCB, Tirado DG, Martín SHC, et al. Actuación diagnóstica ante hipertransaminasemia en pediatría: documento de consenso de Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica (SEGHNP), Asociación Española de Pediatría de Atención Primaria (AEPap) y Sociedad Española de Pediatría de Atención Primaria (SEPEAP). An Pediatr (Barc). 2022; 96(5): 448.e1. https://doi.org/10.1016/j.anpede.2022.04.009
  2. Lee TH, Kim WR, Poterucha JJ. Evaluation of elevated liver enzymes. Clin Liver Dis. 2012; 16(2): 183-98. https://doi.org/10.1016/j.cld.2012.03.006
  3. Costa JM, Pinto SM, Santos-Silva E, Moreira-Silva H. Incidental hypertransaminasemia in children-a stepwise approach in primary care. Eur J Pediatr. 2023; 182(4): 1601-9. https://doi.org/10.1007/s00431-023-04825-4
  4. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017; 112(1): 18-35. https://doi.org/10.1038/ajg.2016.517
  5. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98(5): 960-7. https://doi.org/10.1111/j.1572-0241.2003.07486.x
  6. Gilbert-Barness E, Barness LA, Farrell PM. Clinical Use of Pediatric Diagnostic Tests. 3rd ed. Philadelphia: Lippincott, Williams & Wilkins; 2003.
  7. Serdaroğlu F, Koca T, Dereci S, Akçam M. The etiology of hypertransaminasemia in Turkish children. Bosn J Basic Med Sci. 2016; 16(2): 151-6. https://doi.org/10.17305/bjbms.2016.982
  8. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6): 1966-86. https://doi.org/10.1097/HEP.0000000000000520
  9. European Association for the Study of the Liver. European Association for the Study of the Liver EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019; 70: 1222-61. https://doi.org/10.1016/j.jhep.2019.02.014
  10. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020; 72(2): 671-722. https://doi.org/10.1002/hep.31065
  11. Duggan MB. Anthropometry as a tool for measuring malnutrition: impact of the new WHO growth standards and reference. Ann Trop Paediatr 2010; 30: 1-17. https://doi.org/10.1179/146532810X12637745451834
  12. Karimzadeh P, Ahmadabadi F, Jafari N, Jabbehdari S, Alaee MR, Ghofrani M,et al. Biotinidase deficiency: a reversible neurometabolic disorder (an Iranian pediatric case series). Iran J Child Neurol. 2013; 7(4): 47-52.
  13. Iorio R, Sepe A, Giannattasio A Cirillo F, Vegnente A. Hypertransaminasemia in childhood as a marker of genetic liver disorders. J Gastroenterol. 2005; 40(8): 820-6. https://doi.org/10.1007/s00535-005-1635-7
  14. Sanrı A, Kırsaçlıoğlu TC, Sanrı E, Şaylı TR. Etiological evaluation of the elevated trasnaminases in children. CMJ. 2020; 42(1): 56-64. https://doi.org/10.7197/cmj.vi.593477
  15. Çeltik C, Erbaş H, Kurşun ÖS, Bostancıoğlu M, İnan M, Öner N, et al. The Reasons of Elevated Serum Transaminases in Childhood. Turk J Biochem. 2008; 33(4): 175-81.
  16. Bugeac N, Pacht A, Mandel H, Iancu T, Tamir A, Srugo I, et al. The significance of isolated elevation of serum aminotransferases in infants and young children. Arch Dis Child. 2007; 92(12): 1109-12. https://doi.org/10.1136/adc.2007.121194
  17. Kang KS. Abnormality on liver function test. Pediatr Gastroenterol Hepatol Nutr. 2013; 16(4): 225-32. https://doi.org/10.5223/pghn.2013.16.4.225
  18. Vos MB, Abrams SH, Barlow SE, aprio S, Daniels SR, Kohli R, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017; 64(2): 319-34. https://doi.org/10.1097/MPG.0000000000001482
  19. Stroes AR, Vos M, Benninga MA, Koot BGP. Pediatric MASLD: current understanding and practical approach. Eur J Pediatr. 2024; 184(1): 29. https://doi.org/10.1007/s00431-024-05848-1
  20. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One 2015; 10: e0140908. https://doi.org/10.1371/journal.pone.0140908
  21. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118(04): 1388-93. https://doi.org/10.1542/peds.2006-1212
  22. Janczyk W, Socha P. Non-alcoholic fatty liver disease in children. Clin Res Hepatol Gastroenterol. 2012; 36(3): 297-300.https://doi.org/10.1016/j.clinre.2012.03.026
  23. Vajro P, Maddaluno S, Veropalumbo C. Persistent hypertransaminasemia in asymptomatic children: a stepwise approach. World J Gastroenterol. 2013; 19(18): 2740-51.https://doi.org/10.3748/wjg.v19.i18.2740
  24. Amin MD, Harpavat S, Leung DH. Drug-induced liver injury in children. Curr Opin Pediatr. 2015; 27(5): 625-33. https://doi.org/10.1097/MOP.0000000000000264
  25. Monge-Urrea F, Montijo-Barrios E. Drug-induced Liver Injury in Pediatrics. J Pediatr Gastroenterol Nutr. 2022; 75(4): 391-5.https://doi.org/10.1097/MPG.0000000000003535

Telif hakkı ve lisans

Telif hakkı © 2025 Yazar(lar). Açık erişimli bu makale, orijinal çalışmaya uygun şekilde atıfta bulunulması koşuluyla, herhangi bir ortamda veya formatta sınırsız kullanım, dağıtım ve çoğaltmaya izin veren Creative Commons Atıf Lisansı (CC BY) altında dağıtılmıştır.

Nasıl atıf yapılır

1.
Arslan M. Etiology and clinical features of hypertransaminasemia in children: A retrospective study from a tertiary care center in Türkiye. Turk J Pediatr Dis. 2026;20(1):52-57. https://doi.org/10.12956/TJPD.2025.1226